A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
A phase 2 trial of VS-7375, Cetuximab, Panitumumab in colorectal cancer, run by Verastem, Inc., now recruiting.
Overview
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer is a phase 2 interventional study registered as NCT07659795 by Verastem, Inc., with 150 participants planned, started 2026-07-28 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Shares VS-7375, Verastem Oncology, Cetuximab.
- TrialA Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Shares VS-7375, Verastem Oncology, Cetuximab, Colorectal cancer.
- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Shares VS-7375, Verastem Oncology.
- PairingAnti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC
Shares Panitumumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Cetuximab, Colorectal cancer.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Cetuximab, Colorectal cancer.
- TrialStudy of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal
Shares Panitumumab, Colorectal cancer.
- TrialPARADIGM
Shares Panitumumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Shares Cetuximab, Colorectal cancer.